

# AGENDA & MEETING NOTICE

## Washington State Pharmacy and Therapeutics Committee

**Date:** 06/15/05

**Time:** 9:00 a.m. – 4:00 p.m.

**Location:** Radisson Hotel SeaTac, 17001 Pacific Highway South, Seattle, WA 98188

### Agenda

\* Times are approximate and subject to change.

9:00 a.m. – 9:05 a.m.	Welcome & Introductions	Daniel Lessler, M.D. P&T Committee Chairman
9:05 a.m. – 10:15 a.m.	Drug Class review – <b>New Class</b> Alzheimer / Stakeholder Comment	OHSU EPC Staff <i>Limit 3 minutes per person for stakeholder comment</i>
10:15 a.m. – 10:45 a.m.	Drug Class review – <b>Update</b> Skeletal Muscle Relaxants / Stakeholder Comment	Daniel Lessler, M.D. <i>Limit 3 minutes per person for stakeholder comment</i>
10:45 a.m. – 11:00 a.m.	Break	All
11:00 a.m. – 12:00 p.m.	Drug Class Review – <b>Update</b> Long Acting Opioids / Stakeholder Comment	OHSU EPC Staff <i>Limit 3 minutes per person for stakeholder comment</i>
12:00 p.m. – 12:45 p.m.	Lunch ( <i>on your own</i> )	
12:45 p.m. – 1:20 p.m.	Drug Class review – <b>Update</b> Calcium Channel Blockers / Stakeholder Comment	OHSU EPC Staff <i>Limit 3 minutes per person for stakeholder comment</i>
1:20 p.m. – 1:50 p.m.	Drug Class review – <b>Update</b> Over Active Bladder / Stakeholder Comment	Daniel Lessler, M.D. <i>Limit 3 minutes per person for stakeholder comment</i>
1:50 p.m. – 2:20 p.m.	Drug Class Review – <b>Update</b> Oral Hypoglycemics / Stakeholder Comment	Daniel Lessler, M.D. <i>Limit 3 minutes per person for stakeholder comment</i>
2:20 p.m. – 2:30 p.m.	Break	All
2:30 p.m. – 4:00 p.m.	DUR: MAA's Mental Health Drug Initiatives  1. <i>Background:</i> MAA has been working with community stakeholders since December 2004 to study best practices to insure the safe and effective use of 2nd generation antidepressants and the appropriate use of second-line anticonvulsants (Neurontin, Topamax, Keppra, and Gabitril). The stakeholder's work included evaluating mental health models from other Medicaid programs such as Massachusetts and Missouri.  2. <i>Today's presentation:</i> Dr. Thompson will present MAA's proposals that represent the collaborative work completed with community stakeholders. Best practices from Massachusetts and Missouri and been incorporated into MAA's Business Plan.  3. <i>Expected Outcome:</i> The DUR Board will recommend proceeding with the implementation of MAA's proposed mental health initiatives for 2nd generation antidepressants and for the appropriate use of Neurontin, Topamax, Keppra, and Gabitril.	Jeff Thompson, M.D. MAA Medical Director
4:00 p.m.	Adjourn	

### Additional Information

Special notes:

If you are a person with a disability and need a reasonable accommodation or have questions, please call Erika Clayton at (206) 521-2027 or send an email to [pdp@hca.wa.gov](mailto:pdp@hca.wa.gov).